23934-85-2

Basic information

• Product Name: 4-(benzylamino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one
• Synonyms: 4-(benzylamino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one
• CAS NO: 23934-85-2
• Molecular Weight: 293.368
• Mol File: 23934-85-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-(benzylamino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(benzylamino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one(23934-85-2)
• EPA Substance Registry System: 4-(benzylamino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one(23934-85-2)

Safety Data

• Hazardous Substances Data: 23934-85-2(Hazardous Substances Data)

Upstream product

• 83-07-8 4-amino-2,3-dimethyl-1-phenylpyrazolin-5-one 
• 100-39-0 benzyl bromide 
• 100-51-6 benzyl alcohol 
• 30672-29-8 1,5-dimethyl-4-nitro-2-phenyl-1H-pyrazole-3(2H)-one 
• 100-52-7 benzaldehyde 
• 83-17-0 N-(phenylmethylene)-1,5-dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one 
• 100-44-7 benzyl chloride 

Downstream Products

• 102892-04-6 N-benzyl-N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-salicylamide 
• 110049-83-7 chloro-acetic acid-[benzyl-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-amide] 
• 119210-63-8 N-benzyl-N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-benzamide 
• 102660-18-4 2-bromo-propionic acid-[benzyl-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-amide] 

Relevant articles and documents

Microwave assisted Biology-Oriented Drug Synthesis (BIODS) of new N,N′-disubstituted benzylamine analogous of 4-aminoantipyrine against leishmaniasis – In vitro assay and in silico-predicted molecular interactions with key metabolic targets

Biology-Oriented Drug Synthesis (BIODS) deals with the simple chemical transformations on the commercially available drugs in order to enhance their new and diversified pharmacological profile. It opens new avenues for the rapid development of drug candidates for neglected tropical diseases (NTDs). Leishmaniasis is one of the NTDs which spread by the bite of sandflies (plebotomine). It ranges from cutaneous self-healing leishmaniasis to life threatening visceral leishmaniasis, known as kala-azar. The current treatment options include the use of pentamidine, miltefosine, and amphotericin B drugs. Unfortunately, all currently available drugs are associated with adverse effects, such as severe nephron- and cardiotoxicity, pancreatitis, and hepatotoxicity. This warrants the development of new drugs against leishmaniasis. Moreover, emergence of resistance against the current medications further worsens the conditions. With this objective, new N, N′-disubstituted benzylamine derivatives of ampyrone (4-aminoantipyrine) were synthesized by using ultrasonication, and microwave assistance. All derivatives were found to be new, except 1, 4, and 11. All the compounds were evaluated for their anti-leishmanial activity, and cellular cytotoxicity. Among them, compounds 4, 5, 8, and 9 showed a significant anti-leishmanial activity in vitro, in comparison to standard drug, miltefosine (IC50 = 25.78 ± 0.2 μM). These compounds were also docked against various metabolic enzymes to predict their interactions and mechanism of action, and were found to act via targeting important enzymes of various metabolic pathways.